Skip to main content

Compass Therapeutics, Inc.

CMPX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001738021

In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Compass Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $2.85K in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$2.85K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Compass Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Compass Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lerner NeilChief Accounting Officer400,000Sep 25, 20263
Anderman JonathanGeneral Counsel196,000Apr 30, 20262
Schuetz Thomas J.CHIEF EXECUTIVE OFFICER6,603,336Feb 10, 20264
Lindahl Richard SDirector–Jan 5, 20261
Gray Mary AnnDirector–Jan 5, 20261
Gordon Carl LDirector0IndirectJan 5, 20261
Chiniara EllenDirector–Jan 5, 20261
Shin BarryCFO525,000Jan 5, 20261
Sirard CynthiaChief Medical Officer–Jan 5, 20261
Ferneau PhilipDirector–Jan 5, 20261
Boylan James PDirector–Jan 5, 20261
Prasad ArjunChief Commercial Officer–Jan 5, 20261
OrbiMed Advisors LLCDirector, 10% Owner0IndirectApr 11, 20250
OrbiMed Capital GP VI LLCDirector, 10% Owner0IndirectApr 11, 20250
OrbiMed Genesis GP LLCDirector, 10% Owner0IndirectApr 11, 20250
Bisker-Leib VeredCHIEF EXECUTIVE OFFICER3,124,426Feb 9, 20240
Wurzer David MDirector–Feb 10, 20230
OrbiMed Capital GP V LLCDirector, 10% Owner15,219,994IndirectNov 10, 20220
Squinto Stephen PDirector–Feb 23, 20220
Kaplan BrettDirector–Feb 23, 20220
Kalled SusanChief Scientific Officer–Feb 23, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 25, 2026 (view filing)8:01 AM ETSep 241 dayLerner NeilChief Accounting OfficerPPurchase+2.50K$1.14+$2.85K+0.6%400.0K after
Apr 30, 2026 (view filing)Apr 291 dayLerner NeilChief Accounting OfficerPPurchase+15.0K$1.89+$28.4K+3.9%397.5K afterAmended
Apr 30, 2026 (view filing)Apr 291 dayAnderman JonathanGeneral CounselPPurchase+25.0K$1.89+$47.3K+14.6%196.0K afterAmended
May 27, 2025 (view filing)May 27Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+10.0K$2.11+$21.1K+0.2%6.48M after
Apr 11, 2025 (view filing)7:24 PM ETApr 92 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerSSale−3.57M$1.59−$5.68M−100.0%0 afterDuplicate filing
Apr 11, 2025 (view filing)Apr 92 daysGordon Carl LDirector, 10% OwnerSSale−3.57M$1.59−$5.68M−100.0%0 after
Apr 8, 2025 (view filing)Apr 71 dayAnderman JonathanGen Counsel & Corporate SecPPurchase+20.0K$1.54+$30.8K+2,000.0%21.0K after
Apr 8, 2025 (view filing)Apr 71 dayLerner NeilCHIEF ACCOUNTING OFFICERPPurchase+20.0K$1.42+$28.4K+6.7%320.0K after
Mar 10, 2023 (view filing)Mar 10Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+10.0K$3.37+$33.7K+0.2%6.02M after
Feb 27, 2023 (view filing)Feb 27Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$3.98+$79.6K+0.3%6.01M after
Feb 15, 2023 (view filing)Feb 15Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$3.86+$77.2K+0.3%5.99M after
Jan 31, 2023 (view filing)Jan 31Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$4.05+$81.0K+0.4%5.47M after
Jan 24, 2023 (view filing)Jan 24Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$4.19+$83.8K+0.4%5.45M after
Nov 25, 2022 (view filing)Nov 22-253 daysBisker-Leib VeredChief Operating OfficerSSale−24.5K$4.23−$103.7K−2.3%1.06M after3 lots
Nov 22, 2022 (view filing)Nov 18-214 daysBisker-Leib VeredChief Operating OfficerSSale−22.3K$4.36−$97.0K−2.0%1.08M after2 lots
Nov 10, 2022 (view filing)4:44 PM ETNov 82 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+402.0K$3.21+$1.29M+2.7%15.2M afterDuplicate filing
Nov 10, 2022 (view filing)Nov 82 daysGordon Carl LDirector, 10% OwnerPPurchase+402.0K$3.21+$1.29M+2.7%15.2M after
Sep 28, 2022 (view filing)Sep 28Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+10.0K$2.32+$23.2K+0.2%5.43M after
Sep 27, 2022 (view filing)Sep 261 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$2.27+$34.0K+0.3%5.42M after
Sep 8, 2022 (view filing)Sep 71 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$3.03+$45.5K+0.3%5.41M after
Sep 1, 2022 (view filing)Sep 1Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$2.83+$42.5K+0.3%5.39M after
Aug 17, 2022 (view filing)Aug 17Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$3.05+$45.8K+0.3%5.38M after
Aug 10, 2022 (view filing)Aug 10Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$2.64+$39.6K+0.3%5.36M after
Aug 2, 2022 (view filing)Aug 11 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+15.0K$2.58+$38.7K+0.3%5.35M after
Jun 21, 2022 (view filing)Jun 21Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$2.80+$56.0K+0.4%5.33M after
Jun 17, 2022 (view filing)Jun 161 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$2.34+$46.8K+0.4%5.31M after
Jun 13, 2022 (view filing)Jun 13Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+30.0K$2.29+$68.7K+0.6%5.29M after
Jun 7, 2022 (view filing)Jun 61 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+30.0K$2.83+$84.9K+0.6%5.26M after
Jun 1, 2022 (view filing)Jun 1Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$3.03+$60.6K+0.4%5.23M after
May 26, 2022 (view filing)May 26Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.0K$3.04+$60.8K+0.4%5.21M after
May 24, 2022 (view filing)May 231 daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+18.4K$2.72+$49.9K+0.4%5.19M after
May 17, 2022 (view filing)May 17Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+20.2K$2.47+$49.9K+0.4%5.17M after
May 13, 2022 (view filing)5:45 PM ETMay 11-132 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+192.5K$2.18+$420.5K+1.3%14.8M after3 lotsDuplicate filing
May 13, 2022 (view filing)May 11-132 daysGordon Carl LDirector, 10% OwnerPPurchase+192.5K$2.18+$420.5K+1.3%14.8M after3 lots
May 10, 2022 (view filing)6:21 PM ETMay 6-104 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+125.4K$1.57+$197.3K+0.9%14.6M after3 lotsDuplicate filing
May 10, 2022 (view filing)May 10Same daySchuetz Thomas J.CHIEF EXECUTIVE OFFICERPPurchase+27.8K$1.80+$50.1K+0.5%5.15M after
May 10, 2022 (view filing)May 6-104 daysGordon Carl LDirector, 10% OwnerPPurchase+125.4K$1.57+$197.3K+0.9%14.6M after3 lots
Nov 8, 2021 (view filing)9:06 PM ETNov 44 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+5.36M$3.50+$18.8MNew position3.57M after2 lotsDuplicate filing
Nov 8, 2021 (view filing)Nov 44 daysGordon Carl LDirector, 10% OwnerPPurchase+5.36M$3.50+$18.8MNew position3.57M after2 lots